Geminiguy, you are incorrect on numerous fronts. Even a cursory...

Geminiguy, you are incorrect on numerous fronts. Even a cursory glance at the Sept quarterly would show as much.

1. But for licensing revenue GTG would have gone bust years ago. Look at the cashflows for the past 5 years and this becomes obvious. Dont accuse me of being misleading - where did you pull the figure of $15m in licensing in the last quarter from - try $2.5m in the 6 months to Sept 10. In that quarterly they earnt $3.4m and paid staff $1.5m so if licensing was $2.5m you have a red number. Basic maths.
2. The major patents to which nearly every license has been granted HAS expired. All that is left now is litigation for previous infringement. The last 5 years annual reports will tell you that if you look. The only other junk DNA patent to which major licenses have been granted expires in under 4 years. What new patents could you be referring to - their R & D is dead and you can't exactly re patent the junk DNA IP. Can you be more specific or let me guess you fell for the same old codswallop at the AGM. BTW wouldn't you think that GTG has a disclosure obligation to notify shareholders that its major patent HAS expired!!
3. Jacobson has not negotiated a license in his own right in over 3 years. The only reason licenses have been negotiated is due to the introduction of no license no fee attorneys. That too is in the latest quarterly. He only has a role because he holds control - look what happenned to the last CEO who tried to get rid of him from licensing - he got fired! I am a fan of the current licensing strategy but dont kid yourself that Jacobson has any role in its success - he is more of a handicap given the issues hanging over his head.
4. You appear not to understand how the large US and European heath care markets work. If you want a simple example go and watch the movie Love and other drugs - doctors and specialists buy tests because on the ground salesmen convince them to do so. If you think that Brevagen is a one of a kind diagnostic solution then you simply fail to appreciate the extent of the world healthcare market. Why do you think Brevagen went bust - maybe because it worked diagnostically but failed to sell. The healthcare market is littered with similar examples.
6. They bought Brevagen for $1.5m because that was all it was worth. A great investment - spend $320m on something now worth $1.5m. Doesnt that tell you somehting is flawed? I wonder how many people looked at Brevagen and said no thanks. Once again Brevagen - like everything else at GTG is misunderstood potential - potential that has not once been delivered on.

The recent share price rise in GTG (as with all of its rises in its history) are based on day trader hype and potential. As i said if you can make money on the trade good luck but dont be so foolish as to think this stock will ever see anything like the heights it has fallen from. The are way too many burnt shareholders out there that will sell into any strength.